SummerHaven Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

SummerHaven Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,851	Closed	-$269K	–	274
2023 Q2	$269K	Sell	13,851 -4,327	-24%	-$103K	0.17%	190
2023 Q1	$516K	Buy	18,178 +570	+3%	+$16.9K	0.3%	184
2022 Q4	$515K	Buy	17,608 +300	+2%	+$9.54K	0.31%	187
2022 Q3	$457K	Sell	17,308 -1,296	-7%	-$47.6K	0.32%	198
2022 Q2	$827K	Hold	18,604	–	–	0.56%	78
2022 Q1	$921K	Buy	18,604 +862	+5%	+$41.4K	0.52%	86
2021 Q4	$903K	Hold	17,742	–	–	0.49%	98
2021 Q3	$990K	Buy	+17,742	New	+$873K	0.58%	23

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SummerHaven Investment Management's EGRX Position: Q3 2023 in Review

SummerHaven Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 13,851 shares — an estimated $269K sold.

SummerHaven Investment Management first reported a position in EGRX in Q3 2021 and held it in 8 quarters. The position peaked at $990K in Q3 2021. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

SummerHaven Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
SummerHaven Investment Management sold 13,851 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $269K.
SummerHaven Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2021 and held it in 8 quarters.
SummerHaven Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $990K in Q3 2021.
107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on SummerHaven Investment Management's 13F filing for Q3 2023, filed 13 Oct 2023.